Magnesium oxide nanoparticles (MgO NPs) have emerged as potential materials for various biomedical applications due to their unique physicochemical properties, including biodegradability, biocompatibility, cationic capacity, high stability and redox properties. MgO NPs have become an attractive platform to combat microbes and may be a promising alternative to overcome challenges associated with eliminating microbial biofilms and antibiotic resistance. Hence, due to the increasing use of MgO NPs in biomedicine, new synthetic strategies for MgO NPs are necessary. MgO NPs synthesised using green methods are non-toxic, eco-friendly and have high stability for a wide range of biological, medical and catalytic applications. This review presents the recent advances in biosynthesis strategies of MgO NPs by diverse bio-templates, such as plant, bacterial, fungal and algal extracts. Its photocatalytic properties show a suitable inhibitory function against pathogenic agents, such as microbial proliferation, biofilm formation and fungal growth. Furthermore, MgO NPs and relevant nanocomposites are comprehensively discussed regarding the mechanisms of their effect on microbes, biofilms and fungal strains, as well as challenges and future perspectives.

In recent decades, there has been a significant amount of research into breast cancer, with some important breakthroughs in the treatment of both primary and metastatic breast cancers. It's a well-known fact that treating breast cancer is still a challenging endeavour even though physicians have a fantastic toolset of the latest treatment options at their disposal. Due to limitations of current clinical treatment options, traditional chemotherapeutic drugs, and surgical options are still required to address this condition. In recent years, there have been several developments resulting in a wide range of treatment options. This review article discusses the cellular and molecular foundation of chemotherapeutic drugs, endocrine system-based treatments, biological therapies, gene therapy, and innovative techniques for treating breast cancer.

Multifunctional nano-contrast agent carriers are redefining molecular imaging by combining high-fidelity visualization with targeted delivery, controlled release, and, increasingly, therapeutic action. This review encompasses the development of nano-contrast platforms from conventional dendrimer, liposome, chitosan, and silica systems to modular nano-contrast platforms for multimodal, multi-parametric, and activatable imaging in clinically relevant environments. We dissect engineering strategies that govern surface chemistry, ligand organization, stimulus responsiveness, and microenvironmental sensing, and relate them to theranostic performance, immune system engagement, and quantitative image readouts. Biodistribution, pharmacokinetics, and safety are discussed from both classical and model-informed perspectives, with design principles that favor predictable behavior, manufacturability, and regulatory acceptance. Current clinical translation, regulatory pathway evolution, and market dynamics are critically reviewed to elucidate that a few nano-contrast agents have reached patients despite a widespread experimental landscape. Finally, we discuss emerging trends, including biomimetic and ultrasmall carriers, metal–organic and hybrid frameworks, AI-assisted design, digital twins, and precision medicine workflows, which are likely to shape the next-generation nano-contrast theranostics. By systematically relating material selection and carrier architecture to imaging function and translational limitations, this review suggests concrete research priorities for taking nano-contrast agents from sophisticated prototypes to robust, patient-tailored tools.